Vitiligo

15 trials 5 recruiting MedDRA PT
15 Registered trials
5 Recruiting
8 Unique sponsors
10 Unique IMPs
10 Commercial trials
Drug classes (ATC)
D Dermatology (ATC D) 1
— ATC code not specified 11
L Oncology (ATC L) 1
V Various (ATC V) 1
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
JAK inhibitor 3 substances
Kinase inhibitor 1 substance
Monoclonal antibody 1 substance
Phase III: 5 Phase II/III: 1 Phase II: 7 Phase I (Other): 2

Filter these 15 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 15 trials

Phase III

5 trials
  • Incyte Corp. Commercial
    POVORCITINIB
    2023-505782-86-00 6 countries 2024 n=203
    Ended
  • Incyte Corp. Commercial
    POVORCITINIB
    2023-506011-18-00 6 countries 2024 n=281
    Ended
  • Incyte Corp. Commercial
    RUXOLITINIB
    2024-513171-41-00 12 countries 2025 n=202
    Recruiting
  • Incyte Corp. Commercial
    4-[3-(CYANOMETHYL)-3-(3',5'-DIMETHYL-1H,1'H-[4,4'-BIPYRAZOL]-1-YL)AZETIDIN-1-YL]-2,5-DIFLUORO-N-[(2S)-1,1,1-TRIFLUOROPROPAN-2-YL]BENZAMIDE; POVORCITINIB
    2024-520107-12-00 13 countries 2025 n=845
    Recruiting
  • Pfizer Inc. Commercial
    RITLECITINIB TOSILATE
    2022-502518-98-00 8 countries 2024 n=355
    Ended

Phase II/III

1 trial
  • Clinuvel Europe Limited Commercial
    AFAMELANOTIDE
    2023-507470-40-00 2 countries 2024 n=40 Orphan
    Recruiting

Phase II

7 trials
  • Incyte Corp. Commercial
    RUXOLITINIB
    2023-503737-22-00 1 country 2023 n=6
    Ended
  • Merck Sharp & Dohme LLC Commercial
    MK-6194
    2023-503502-37-00 5 countries 2024 n=33
    Ended
  • Takeda Development Center Americas Inc. Commercial
    ZASOCITINIB
    2025-522309-40-00 4 countries 2026 n=144
    Recruiting
  • Centre Hospitalier Universitaire De Bordeaux Academic
    ANIFROLUMAB
    2024-512041-17-00 1 country 2023 n=48
    Recruiting
  • Centre Hospitalier Universitaire De Nantes Academic
    IMP not specified
    2023-507451-30-00 1 country 2024 n=140
    Ended
  • Centre Hospitalier Universitaire De Nantes Academic
    OXYGEN
    2025-524709-34-00 1 country n=5
    Pending
  • I.F.O. Istituti Fisioterapici Ospitalieri Academic
    PIOGLITAZONE
    2025-523266-24-00 1 country n=60
    Pending

Phase I (Other)

2 trials
  • Pfizer Inc. Commercial
    IMP not specified
    2023-505603-23-00 1 country 2024 n=12
    Ended
  • Pfizer Inc. Academic
    RITLECITINIB TOSILATE
    2022-502872-22-00 1 country 2023 n=12
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Incyte Corp. Commercial 5 Phase II, Phase III 2
Pfizer Inc. Commercial 3 Phase I (Other), Phase III 0
Centre Hospitalier Universitaire De Nantes Academic 2 Phase II 0
Clinuvel Europe Limited Commercial 1 Phase II/III 1
Merck Sharp & Dohme LLC Commercial 1 Phase II 0
Takeda Development Center Americas Inc. Commercial 1 Phase II 1
Centre Hospitalier Universitaire De Bordeaux Academic 1 Phase II 1
I.F.O. Istituti Fisioterapici Ospitalieri Academic 1 Phase II 0
New trials by year
2023
3
2024
7
2025
2
2026
1
← All indication landscapes